	US 12,295,941 B2
	Viral inhibitors, the synthesis thereof, and intermediates thereto
Jeffrey Scott Depue, Windham, NH (US); Suresh Kumar Tipparaju, Arlington, MA (US); Helge Alfred Reisch, Sarasota, FL (US); Datong Tang, Weston, MA (US); and Kishore Ramachandran, Westford, MA (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Jul. 18, 2024, as Appl. No. 18/777,501.
Application 18/777,501 is a continuation of application No. 18/379,047, filed on Oct. 11, 2023.
Claims priority of provisional application 63/415,438, filed on Oct. 12, 2022.
Prior Publication US 2024/0366647 A1, Nov. 7, 2024
Int. Cl. A61K 31/7056 (2006.01); A61K 9/00 (2006.01); A61K 31/4184 (2006.01); C07H 19/052 (2006.01)

CPC A61K 31/4184 (2013.01) [A61K 9/0053 (2013.01); A61K 31/7056 (2013.01); C07H 19/052 (2013.01)]

20 Claims

1. A method of preparing maribavir polymorph Form VI, wherein the method comprises crystallizing maribavir Form VI from a crystallization mixture comprising maribavir, or a pharmaceutically acceptable salt thereof, and isopropyl acetate.